Overview

Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

Status:
Recruiting
Trial end date:
2023-10-23
Target enrollment:
Participant gender:
Summary
A clinical trial to investigate the pharmacokinetics, safety and tolerability of CHF6001 after single administrations in participants with mild, moderate and severe liver impairment with matched healthy adult volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.